Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-28T17:51:42.917Z Has data issue: false hasContentIssue false

Paliperidone – a costly option for schizophrenia

Published online by Cambridge University Press:  02 January 2018

Paraskevi Nikolaidou
Affiliation:
email: paraskevi.n@nsft.nhs.uk
Marinos Chatzopoulos
Affiliation:
Norfolk and Suffolk NHS Foundation Trust
Dionysis Seretis
Affiliation:
the Open University
Albert Michael
Affiliation:
Norfolk and Suffolk NHS Foundation Trust, Wedgwood House, Bury-St-Edmunds, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2013

Lepping & Malik’s analysis Reference Nussbaum and Stroup1 of the conditions placed on patients subject to a community treatment order (CTO) in England and Wales, and suggestions for improving their robustness, is timely. We have only recently seen the results of the OCTET study published in The Lancet, 2 which showed that CTOs are no more effective in reducing rates of readmission to hospital than Section 17 leave. The study also found that CTOs confer no greater benefits for patients in terms of clinical or social functioning. In the authors’ words, ‘their current high usage should be urgently reviewed’.

There are two points made by Lepping & Malik that might be elaborated on.

The first is that CTOs ‘have been very popular with treating teams and clinicians’. This suggests all psychiatrists are in favour of CTOs. In fact, the use of CTOs has varied considerably, and one consultant psychiatrist has gone on record saying: ‘I have not used CTOs in my practice despite having a large community caseload, and have removed CTOs if patients are transferred to my care on them. I justify this because they lack an evidence base’. Reference Kahn, Fleischhacker, Boter, Davidson, Vergouwe and Keet3 We should not forget either that there have been occasions when approved mental health professionals (AMHPs) - often forgotten in this whole debate - have vetoed clinicians’ applications.

Second, the authors suggest that CTOs ‘have been used more than anticipated’. Certainly, their use has been higher than the Department of Health estimated at the time. However, estimates have been published by the King’s Fund, based on my own analysis, Reference Chue and Chue4 which suggested that in the first years of a new act, up to 5000 people would be placed under an order (pretty much reflecting the numbers today), and that the use of orders in England and Wales was likely to build over a period of some 10-15 years to between 7800 and 13 000 people in total.

It remains to be seen whether the latter estimate will be accurate. Much will depend on whether clinicians change their practice in the light of the OCTET evidence. There is certainly an urgent need for the Department of Health and the Royal College of Psychiatrists to encourage clinicians to limit CTO applications only to genuinely ‘revolving door’ patients with impaired decision-making (as in Scotland), a history of non-engagement followed by relapse with significant risk to self or others, and a known positive response to medication given.

Of course, in the light of both past reviews pointing to a lack of evidence that CTOs are associated with any positive outcomes, Reference Hough, Lindenmayer, Gopal, Melkote, Lim and Herben5 and the recent OCTET findings, there is a strong argument for repealing the CTO powers completely. Whether or not there is the political will to do so is another matter.

References

1 Nussbaum, AM, Stroup, TS. Drug information update: paliperidone palmitate for schizophrenia. Psychiatrist 2013; 37: 164–6.Google Scholar
2 BMA, Royal Pharmaceutical Society. British National Formulary (BNF) 65, March–September 2013. BMJ Group & Pharmaceutical Press, 2013.Google Scholar
3 Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IPW, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085–97.CrossRefGoogle ScholarPubMed
4 Chue, P, Chue, J. A review of paliperidone palmitate. Expert Rev Neurother 2012; 12: 1383–97.Google Scholar
5 Hough, D, Lindenmayer, JP, Gopal, S, Melkote, R, Lim, P, Herben, V, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1022–31.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.